- Home
- CRBP vs IAF Comparison
CRBP vs IAF Comparison
Compare CRBP & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- IAF
- Stock Information
- Founded
- CRBP 2009
- IAF 1985
- Country
- CRBP United States
- IAF United States
- Employees
- CRBP N/A
- IAF N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- IAF Finance/Investors Services
- Sector
- CRBP Health Care
- IAF Finance
- Exchange
- CRBP Nasdaq
- IAF Nasdaq
- Market Cap
- CRBP 110.3M
- IAF 123.6M
- IPO Year
- CRBP N/A
- IAF N/A
- Fundamental
- Price
- CRBP $8.90
- IAF $4.53
- Analyst Decision
- CRBP Strong Buy
- IAF
- Analyst Count
- CRBP 10
- IAF 0
- Target Price
- CRBP $53.56
- IAF N/A
- AVG Volume (30 Days)
- CRBP 124.3K
- IAF 90.4K
- Earning Date
- CRBP 08-05-2025
- IAF 01-01-0001
- Dividend Yield
- CRBP N/A
- IAF 11.44%
- EPS Growth
- CRBP N/A
- IAF N/A
- EPS
- CRBP N/A
- IAF N/A
- Revenue
- CRBP N/A
- IAF N/A
- Revenue This Year
- CRBP N/A
- IAF N/A
- Revenue Next Year
- CRBP $270.04
- IAF N/A
- P/E Ratio
- CRBP N/A
- IAF N/A
- Revenue Growth
- CRBP N/A
- IAF N/A
- 52 Week Low
- CRBP $4.64
- IAF $3.60
- 52 Week High
- CRBP $61.89
- IAF $4.59
- Technical
- Relative Strength Index (RSI)
- CRBP 53.56
- IAF 59.59
- Support Level
- CRBP $9.10
- IAF $4.41
- Resistance Level
- CRBP $9.80
- IAF $4.54
- Average True Range (ATR)
- CRBP 0.62
- IAF 0.04
- MACD
- CRBP 0.01
- IAF -0.00
- Stochastic Oscillator
- CRBP 31.45
- IAF 92.31
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.